


DHFR-IN-12

Cat. No.:	HY-149699
Molecular Formula:	C ₂₈ H ₂₅ N ₅ O ₃
Molecular Weight:	479.53
Target:	Dihydrofolate reductase (DHFR)
Pathway:	Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	DHFR-IN-12 (Compound 5c) is a DHFR inhibitor which has good antibacterial activity ^[1] .	
In Vitro	DHFR-IN-12 (Compound 5c, 521 μM) with excellent antibacterial activity ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
In Vivo	DHFR-IN-12 (5% w/v; 3 days) can significantly reduce keratitis infection in rats. Compared with MRSA group, the % of corneal opacity IN DHFRin-12 treated group was significantly reduced ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	Adult male Sprague–Dawley rats (200 ± 15 g) ^[1]
	Dosage:	(5% w/v; 3 days)
	Administration:	Dripping on the cornea
	Result:	Reduced keratitis infection in rats. Compared with MRSA group, the % of corneal opacity was significantly reduced.

REFERENCES

[1]. Mansour B, et al. New Pyrazole-Clubbed Pyrimidine or Pyrazoline Hybrids as Anti-Methicillin-Resistant Staphylococcus aureus Agents: Design, Synthesis, In Vitro and In Vivo Evaluation, and Molecular Modeling Simulation[J]. ACS Omega, 2023.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA